Sino Biopharmaceutical (HKG:1177) presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a Friday Hong Kong bourse filing said.
The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.
The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.
The overall safety of the trial group was also good.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。